AstraZeneca is strengthening its uncommon illness pipeline with an settlement to accumulate Amolyt Pharma, a biotech firm in late-stage growth of a remedy designed to deal with a uncommon hormone deficiency whose solely FDA-approved remedy will quickly be can be discontinued. Beneath deal phrases introduced Thursday, AstraZeneca pays Amolyt shareholders $800 million upfront. One other $250 million is tied to […]